Study demonstrates the concept of systemic gene therapy treatment for gamma-sarcoglycanopathy

NewsGuard 100/100 Score

Gamma-sarcoglycanopathy (LGMD2C) is one of the most common limb-girdle myopathies. It affects less than 10 people per 1,000,000 and is characterized by progressive muscle weakness in the pelvis (pelvic girdle) and shoulders (scapular girdle), linked to mutations in the SGCG gene encoding gamma-sarcoglycan. There is currently no cure for this neuromuscular disease.

In this study, Isabelle Richard's team:

  • demonstrated the concept of systemic gene therapy treatment: an AAV8 drug vector expressing deficient gamma-sarcoglycan allowed the protein to be reexpressed in the treated muscle after injection in mouse models of the disease,
  • determined the effective treatment dose: Three different doses were tested. The drug vector restored, with the highest dose, an almost complete expression of the deficient SGCG gene. The researchers observed that the proportion of corrected muscle fibres is less than 5% with the lowest dose, between 25% and 75% with the intermediate dose and between 75% and 100% with the highest dose (see figure)

In addition, the researchers also observed the consequences of physical exercise on muscle fibres and found that at the highest dose the treatment allows the treated muscle fibres to resist stress.

"This study is the result of several years of work. Indeed, we had already tested another vector that proved to be well tolerated but with limited gene expression. Thanks to this work, we have determined the vector and dose that would be effective in patients and today we have the means to work on a clinical trial," enthuses Isabelle Richard, lead author of the work.

In 2006, a first phase I gene therapy clinical trial, lead by Genethon, tested the efficacy of an AAV1 vector injected intramuscularly in nine patients. One month after injection, the researchers found that the product was well tolerated and that the therapeutic gene was present in patients treated at the highest dose but in limited quantities (Results published in Brain, January 11, 2012).



Journal reference:

Israeli, D. et al. (2019) A dose response study in γ–sarcoglycanopathy mouse model in the context of mechanical stress. Molecular Therapy: Methods & Clinical Development.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel gene-delivery vehicle shows promise for treating brain disorders